Natus Medical Announces Executive Transition
17 Décembre 2021 - 10:01PM
Natus Medical Incorporated (NASDAQ:NTUS) (the
“Company” or “Natus”), a leading provider of medical device
solutions focused on the diagnosis and treatment of central nervous
and sensory system disorders for patients of all ages, today
announced the appointment of Thomas J. Sullivan as President &
Chief Executive Officer effective December 27, 2021 and a focus on
long-term growth.
Earlier this year, the Board of Directors
engaged a strategic consulting firm to assist it in developing a
strategy to build upon Natus’ market leading positions. Following
the review, the Board retained Egon Zehnder to conduct a succession
planning process which reviewed a talented slate of internal and
external candidates to lead Natus. In appointing Mr. Sullivan, the
Board has selected a 20+ year medical device veteran with extensive
global executive experience and diverse expertise in strategic
planning, operational excellence, organizational development,
business transformation, M&A, and public company
leadership.
“We are thrilled to have Tom assume the
leadership of Natus at this exciting time for our Company. He is a
proven business leader with a long track record of success at
creating shareholder value. As a Natus Independent Director these
past three years, he has shown his strategic insight and drive for
Natus’ potential for market leadership through holistic business
model execution,” said Joshua H. Levine, Chairman of the Board of
Directors. Mr. Levine added, “the Board would like to thank
Jonathan Kennedy for successfully positioning the Company for its
next phase of innovation and growth.”
“I am excited at the opportunity to join the
Natus leadership team to help realize the great promise of the
Company. As a Board Member, I have admired the passionate
commitment of our Natus Teammates to the patients that our products
impact and am humbled by the opportunity to join them in their
mission. Together we will build upon the Natus heritage of
innovation and market leadership to drive growth while advancing
the standard of care for healthcare professionals in the diagnosis,
monitoring, and treatment of impairments of the central nervous and
sensory systems,” said Mr. Sullivan.
Prior to joining Natus, Mr. Sullivan was the
President & Chief Executive Officer of Spectrum Plastics Group,
an industry leading medical device global contract manufacturer. In
earlier roles, he led multiple public and privately owned medical
device companies including A&E Medical, Symmetry Surgical, and
Symmetry Medical. In addition, Mr. Sullivan held numerous executive
roles at Johnson & Johnson from 1990 to 2011 including
President of J&J Medical Products Canada and the billion-dollar
U.S. Orthopedics division. Mr. Sullivan graduated as a Palmer
Scholar from The Wharton School at the University of Pennsylvania
in 1991 where he earned an MBA in Strategic Management and
Information Technology. He also holds a Bachelor of Science magna
cum laude in Applied Mathematics and Computer Science from the
University of Pittsburgh. He is active in local New Jersey
charities as well as the National Multiple Sclerosis Society. Mr.
Sullivan has earned the National Association of Corporate Directors
(NACD) Directorship Certification®.
The Natus Nominating & Governance Committee
of the Board of Directors has been conducting a search process that
will ensure the Board’s composition is best positioned for company
success and regulatory compliance. The Board expects to fill the
newly open Independent Director role through this process.
About Natus Medical
Incorporated
Natus is a leading provider of medical device
solutions focused on the diagnosis and treatment of central nervous
and sensory system disorders for patients of all ages. Additional
information about Natus Medical can be found at www.natus.com.
Forward-Looking Statements
This press release contains forward-looking
statements, which are generally statements that are not historical
facts. Forward-looking statements can be identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans”, “will”, “outlook” and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. These statements relate to current estimates and assumptions
of our management as of the date of this press release and involve
known and unknown risks, uncertainties and other factors that may
cause actual results, levels of activity, performance, or
achievements to differ materially from those expressed or implied
by the forward-looking statements. Forward-looking statements are
only predictions and the actual events or results may differ
materially. Natus cannot provide any assurance that its future
results or the results implied by the forward-looking statements
will meet expectations. The Company's future results could differ
materially due to a number of factors, including supply chain
delays and constraints, the business, social and economic impact of
the COVID-19 pandemic on the Company's business and results of
operations, the ability of the Company to realize the anticipated
benefits from its new structure or from its consolidation strategy,
effects of competition, the Company's ability to successfully
integrate and achieve its profitability goals from recent
acquisitions, the demand for Natus products and services, the
impact of adverse global economic conditions and changing
governmental regulations, including foreign exchange rate changes,
on the Company's target markets, the Company's ability to expand
its sales in international markets, the Company's ability to
maintain current sales levels in a mature domestic market, the
Company's ability to control costs, risks associated with bringing
new products to market, and the Company's ability to fulfill
product orders on a timely basis, as well as those factors
identified under the heading Item 1A “Risk Factors” in the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2020. Natus disclaims any obligation to update
information contained in any forward-looking statement, except as
required by law.
Natus Medical IncorporatedB. Drew
DaviesExecutive Vice President and Chief Financial Officer(925)
223-6700InvestorRelations@Natus.com
Natus Medical (NASDAQ:NTUS)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Natus Medical (NASDAQ:NTUS)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024